Relmada Therapeutics Stock Performance
| RLMD Stock | USD 4.08 0.44 12.09% |
The company holds a Beta of 0.0457, which implies not very significant fluctuations relative to the market. As returns on the market increase, Relmada Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relmada Therapeutics is expected to be smaller as well. Relmada Therapeutics right now holds a risk of 4.82%. Please check Relmada Therapeutics treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to decide if Relmada Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Relmada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Relmada Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 12.09 | Five Day Return 4.62 | Year To Date Return (6.64) | Ten Year Return 229.03 | All Time Return (66.00) |
Last Split Factor 1:4 | Dividend Date 2019-09-30 | Last Split Date 2019-09-30 |
1 | Acquisition by Traversa Sergio of 27460 shares of Relmada Therapeutics at 3.9968 subject to Rule 16b-3 | 11/25/2025 |
2 | Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology | 12/03/2025 |
3 | Acquisition by Casamento Charles J of 164000 shares of Relmada Therapeutics at 4.06 subject to Rule 16b-3 | 12/12/2025 |
4 | Insider Buying Relmada Therapeutics CFO Purchases 48,059.80 in Stock | 12/19/2025 |
5 | Relmada Therapeutics Rating Increased to Strong-Buy at Jefferies Financial Group | 12/23/2025 |
6 | Acquisition by Ence Chuck of 82090 shares of Relmada Therapeutics at 2.48 subject to Rule 16b-3 | 01/06/2026 |
7 | Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications | 01/12/2026 |
8 | Relmada Therapeutics, Inc. Receives Consensus Recommendation of Hold from Brokerages | 01/29/2026 |
9 | Relmada regains Nasdaq compliance on minimum bid price - MSN | 02/12/2026 |
| Begin Period Cash Flow | 4.1 M | |
| Total Cashflows From Investing Activities | 51.6 M |
Relmada Therapeutics Relative Risk vs. Return Landscape
If you would invest 427.00 in Relmada Therapeutics on November 21, 2025 and sell it today you would lose (19.00) from holding Relmada Therapeutics or give up 4.45% of portfolio value over 90 days. Relmada Therapeutics is currently generating 0.0367% in daily expected returns and assumes 4.8179% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Relmada, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Relmada Therapeutics Target Price Odds to finish over Current Price
The tendency of Relmada Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.08 | 90 days | 4.08 | about 55.89 |
Based on a normal probability distribution, the odds of Relmada Therapeutics to move above the current price in 90 days from now is about 55.89 (This Relmada Therapeutics probability density function shows the probability of Relmada Stock to fall within a particular range of prices over 90 days) .
Relmada Therapeutics Price Density |
| Price |
Predictive Modules for Relmada Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Relmada Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Relmada Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Relmada Therapeutics is not an exception. The market had few large corrections towards the Relmada Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Relmada Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Relmada Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | 0.05 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | 0.03 |
Relmada Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Relmada Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Relmada Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Relmada Therapeutics had very high historical volatility over the last 90 days | |
| Relmada Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (79.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Relmada Therapeutics currently holds about 211.96 M in cash with (51.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relmada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Relmada regains Nasdaq compliance on minimum bid price - MSN |
Relmada Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Relmada Stock often depends not only on the future outlook of the current and potential Relmada Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Relmada Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 30.2 M | |
| Cash And Short Term Investments | 44.9 M |
Relmada Therapeutics Fundamentals Growth
Relmada Stock prices reflect investors' perceptions of the future prospects and financial health of Relmada Therapeutics, and Relmada Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relmada Stock performance.
| Return On Equity | -1.97 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 258.91 M | ||||
| Shares Outstanding | 73.33 M | ||||
| Price To Earning | (1.27) X | ||||
| Price To Book | 28.82 X | ||||
| EBITDA | (83.89 M) | ||||
| Net Income | (79.98 M) | ||||
| Cash And Equivalents | 211.96 M | ||||
| Cash Per Share | 7.05 X | ||||
| Total Debt | 10.3 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (51.76 M) | ||||
| Earnings Per Share | (1.78) X | ||||
| Market Capitalization | 330.73 M | ||||
| Total Asset | 45.82 M | ||||
| Retained Earnings | (640.88 M) | ||||
| Working Capital | 35.5 M | ||||
| Current Asset | 9.3 M | ||||
| Current Liabilities | 3.06 M | ||||
About Relmada Therapeutics Performance
By analyzing Relmada Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Relmada Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Relmada Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relmada Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 362.83 | 344.69 | |
| Return On Tangible Assets | (2.01) | (2.11) | |
| Return On Capital Employed | (2.13) | (2.02) | |
| Return On Assets | (2.01) | (2.11) | |
| Return On Equity | (2.59) | (2.46) |
Things to note about Relmada Therapeutics performance evaluation
Checking the ongoing alerts about Relmada Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Relmada Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relmada Therapeutics had very high historical volatility over the last 90 days | |
| Relmada Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (79.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Relmada Therapeutics currently holds about 211.96 M in cash with (51.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relmada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Relmada regains Nasdaq compliance on minimum bid price - MSN |
- Analyzing Relmada Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relmada Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relmada Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relmada Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relmada Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Relmada Therapeutics' stock. These opinions can provide insight into Relmada Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Relmada Stock analysis
When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |